Akums Drugs

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE09XN01023
  • NSEID: AKUMS
  • BSEID: 544222
INR
727.50
31 (4.45%)
BSENSE

Aug 10

BSE+NSE Vol: 22.8 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Marksans Pharma
Akums Drugs
Supriya Lifesci.
Viyash Scientifi
Sudeep Pharma
P & G Health Ltd
Sanofi India
Strides Pharma
Sanofi Consumer
Orchid Pharma
Blue Jet Health
Why is Akums Drugs & Pharmaceuticals Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Poor long term growth as Net Sales has grown by an annual rate of 6.00% and Operating profit at 17.74% over the last 5 years
3
Flat results in Mar 26
  • INTEREST(9M) At Rs 70.93 cr has Grown at 116.18%
  • PAT(9M) At Rs 205.31 cr has Grown at -22.12%
4
Stock is technically in a Mildly Bullish range
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
5
With ROE of 8.1, it has a Very Attractive valuation with a 2.5 Price to Book Value
  • Over the past year, while the stock has generated a return of -8.18%, its profits have fallen by -16%
6
Majority shareholders : Promoters
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Akums Drugs should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Akums Drugs for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Akums Drugs
51.44%
-0.26
30.88%
Sensex
-1.65%
-0.49
12.94%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
6.00%
EBIT Growth (5y)
17.74%
EBIT to Interest (avg)
5.32
Debt to EBITDA (avg)
1.37
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.67
Tax Ratio
31.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.35%
ROCE (avg)
11.65%
ROE (avg)
9.37%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
38
Industry P/E
37
Price to Book Value
3.46
EV to EBIT
24.27
EV to EBITDA
17.49
EV to Capital Employed
5.55
EV to Sales
2.21
PEG Ratio
NA
Dividend Yield
0.41%
ROCE (Latest)
20.53%
ROE (Latest)
8.11%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
No Trend
OBV
Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
ROCE(HY)

Highest at 14.30%

OPERATING PROFIT TO INTEREST(Q)

Highest at 7.05 times

NET SALES(Q)

Highest at Rs 1,166.63 cr

PBDIT(Q)

Highest at Rs 174.68 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 14.97%

PBT LESS OI(Q)

Highest at Rs 108.86 cr.

PAT(Q)

Highest at Rs 100.01 cr.

EPS(Q)

Highest at Rs 6.53

-4What is not working for the Company
INTEREST(9M)

At Rs 72.39 cr has Grown at 42.00%

Loading Valuation Snapshot...
Here's what is working for Akums Drugs
Operating Profit to Interest - Quarterly
Highest at 7.05 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 108.86 cr has Grown at 59.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 68.35 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 100.01 cr has Grown at 48.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 67.20 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 1,166.63 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 174.68 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 14.97%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 108.86 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 100.01 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 6.53
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Akums Drugs
Interest - Nine Monthly
At Rs 72.39 cr has Grown at 42.00%
over preceding nine months period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)